Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1425-1439

  Rajendran, Peramaiyan ^a   Ong, Tina H ^b   Chen, Luxi ^a,c   Li, Feng ^a   Shanmugam, Muthu K ^a   Vali, Shireen ^d,e   Abbasi, Taher ^d,e   Kapoor, Shweta ^d,e   Sharma, Ashish ^d,e   Kumar, Alan Prem ^a,c   Hui, Kam M ^b   Sethi, Gautam ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CELLWORKS GROUP INC   (United States)

^e Cellworks Research India Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BUTEIN; CYCLIN D1; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; JANUS KINASE 2; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SURVIVIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHALCONES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; STAT3 TRANSCRIPTION FACTOR;

EID: 79952724023     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1123     Document Type: Article

References (66)

1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-9. (Pubitemid 38402113)
2. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004;127:S51-5.
3. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol 2006;44:798-805.
4. Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009;29:10-7.
5. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009;15:3210-6.
6. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331-4. (Pubitemid 26058558)
7. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008;15:834-43. (Pubitemid 351736406)
8. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
9. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18:45-56.
10. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006;2006:pe30.
11. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?Ann N Y Acad Sci 2009;1171:59-76.
12. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006;1091:151-69. (Pubitemid 47092233)
13. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002;196:641-53. (Pubitemid 35024442)
14. Liu P, Kimmoun E, Legrand A, Sauvanet A, Degott C, Lardeux B, et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 2002;37:63-71. (Pubitemid 34713056)
15. Waris G, Turkson J, Hassanein T, Siddiqui A. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 2005;79:1569-80. (Pubitemid 40459104)
16. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005;24:6406-17. (Pubitemid 41486474)
17. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.
18. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 2008;262:201-13.
19. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 2006;12:7140-8. (Pubitemid 44974515)
20. Choudhari SR, Khan MA, Harris G, Picker D, Jacob GS, Block T, et al. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther 2007;6:112-21. (Pubitemid 46206673)
21. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 2007;47:546-55. (Pubitemid 47331746)
22. Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res 2008;14: 2806-12.
23. Lin L, Amin R, Gallicano GI, GlasgowE, Jogunoori W, Jessup JM, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009;28:961-72.
24. Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 2010;292:197-207.
25. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 2010;334:285-93.
26. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem 2007;282:17340-50. (Pubitemid 47100316)
27. Pandey MK, Sung B, Ahn KS, Aggarwal BB. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol Pharmacol 2009;75:525-33.
28. Wang Y, Chan FL, Chen S, Leung LK. The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase. Life Sci 2005;77:39-51. (Pubitemid 40546375)
29. Kang HM, Kim JH, Lee MY, Son KH, Yang DC, Baek NI, et al. Relationship between flavonoid structure and inhibition of farnesyl protein transferase. Nat Prod Res 2004;18:349-56. (Pubitemid 38787023)
30. Yit CC, Das NP. Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Cancer Lett 1994;82:65-72. (Pubitemid 24211073)
31. Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, et al. Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochim Biophys Acta 2005;1726:309-16.
32. Lee SH, Nan JX, Zhao YZ, Woo SW, Park EJ, Kang TH, et al. The chalcone butein from Rhus verniciflua shows antifibrogenic activity. Planta Med 2003;69:990-4. (Pubitemid 38064686)
33. Kim NY, Pae HO, Oh GS, Kang TH, Kim YC, Rhew HY, et al. Butein, a plant polyphenol, induces apoptosis concomitant with increased caspase-3 activity, decreased Bcl-2 expression and increased Bax expression in HL-60 cells. Pharmacol Toxicol 2001;88:261-6.
34. Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 2000;64:1813-20.
35. Lee SH, Seo GS, Kim HS, Woo SW, Ko G, Sohn DH. 2′,4′, 6′-Tris (methoxy-methoxy)chalcone attenuates hepatic stellate cell proliferation by a heme oxygenase-dependent pathway. Biochem Pharmacol 2006;72:1322-33. (Pubitemid 44572190)
36. Aizu E, Nakadate T, Yamamoto S, Kato R. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-mediated epidermal ornithine decarboxylase induction and skin tumor promotion by new lipoxygenase inhibitors lacking protein kinase C inhibitory effects. Carcinogenesis 1986;7:1809-12.
37. Selvam C, Jachak SM, Bhutani KK. Cyclooxygenase inhibitory flavonoids from the stem bark of Semecarpus anacardium Linn. Phytother Res 2004;18:582-4. (Pubitemid 39079158)
38. Hayashi K, Nagamatsu T, Honda S, Suzuki Y. Butein (3,4,2′,4′- tetrahydroxychalcone) ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. Eur J Pharmacol 1996;316:297-306.
39. Moon DO, Kim MO, Choi YH, Hyun JW, Chang WY, Kim GY. Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. Cancer Lett 2010;288:204-13.
40. Vali S, Pallavi R, Kapoor S, Tatu U. Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype. Syst Synth Biol 2010;4:25-33.
41. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S, et al. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol 2010;65:903-11.
42. Equils O, Nambiar P, Hobel CJ, Smith R, Simmons CF, Vali S. A computer simulation of progesterone and Cox2 inhibitor treatment for preterm labor. PLoS One 2010;5:e8502.
43. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of Akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9: 963-75.
44. Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, et al. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res 2007;13:3024-32. (Pubitemid 46849579)
45. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-8. (Pubitemid 26053453)
46. Brierley MM, Fish EN. Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 2005;25:733-44. (Pubitemid 43071210)
47. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88. (Pubitemid 30339203)
48. Kaur N, Lu B, Monroe RK, Ward SM, Halvorsen SW. Inducers of oxidative stress block ciliary neurotrophic factor activation of Jak/ STAT signaling in neurons. J Neurochem 2005;92:1521-30. (Pubitemid 40389220)
49. Kurdi M, Booz GW. Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS. J Cell Physiol 2007;212: 424-31. (Pubitemid 47025632)
50. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 2002;277:45680-7. (Pubitemid 36159180)
51. Moran DM, Mattocks MA, Cahill PA, Koniaris LG, McKillop IH. Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway. J Surg Res 2008;147:23-33.
52. Zauberman A, Zipori D, Krupsky M, Ben-Levy R. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 1999;18:3886-93. (Pubitemid 29358567)
53. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 1999;274:23013-9.
54. Jin C, Li H, He Y, He M, Bai L, Cao Y, et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 2010;136:267-74.
55. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499-513. (Pubitemid 32531347)
56. Campbell GS, Yu CL, Jove R, Carter-Su C. Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem 1997;272:2591-4. (Pubitemid 27053296)
57. Dasmahapatra G, Nguyen TK, Dent P, Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leukoc Res 2006;30:1263-72. (Pubitemid 44223728)
58. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95. (Pubitemid 30339204)
59. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109: 2293-302. (Pubitemid 46425866)
60. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002;168:466-74. (Pubitemid 34014150)
61. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-93.
62. Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 2002;277:28411-7. (Pubitemid 41079264)
63. Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 2001;21:1621-32. (Pubitemid 32156382)
64. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9. (Pubitemid 43166170)
65. Samoszuk M, Tan J, Chorn G. The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC Complement Altern Med 2005;5:5.
66. Lee SH, Choi WC, Kim KS, Park JW, Yoon SW. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med 2010;16:497-500.